Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Genopole’s Citizens

Genopole governance


The Groupement d’intérêt public (GIP, a form of public-private partnership for missions of public interest) Genopole continues to serve thanks to the unfailing support of its 12 members, five of which are fund providers. The GIP has policy and scientific strategy bodies to guide the assurance of its missions.

The biocluster receives stable support from a number of public entities (French State, Île-de-France Regional Council, etc.) who contribute significant funding for investments in and the functioning of shared-use technological platforms and the teams serving Genopole’s labs and businesses.

GIP Genopole General Meeting

The General Meeting is composed of representatives designated by each member institution. The General Meeting administers and makes all decisions concerning the GIP:

  • adoption of the budget,
  • annual program.

It also deliberates nominations to the Committee for Science, Innovation and Industry (CSII) and elects the president and vice-president.

General Meeting members


Stéphane Beaudet - Portrait

Île-de-France Region

Stéphane Beaudet

President of Genopole

Ministère de l'enseignement supérieur et de la recherche

Ministry of Higher Education, Research and Innovation

Emmanuel Dequier

Member

Conseil départemental de l'Essonne
Essonne Terre d'Avenirs

Essonne, The department

Laure Darcos

Vice-president of the General Meeting

Agglo Grand Paris Sud - Logo

Grand Paris Sud

Stéphane Raffalli

Member

Evry-Courcouronnes - Fondateur de Genopole

Evry-Courcouronnes

Mehdy Zeghouf

Member of Genopole

AFM-Téléthon Evry

AFM-Telethon

Laurence Tiennot-Herment

Membre

UEVE - University of Evry - Logo

Université d'Evry

Patrick Curmi

Member

CEA

CEA

Elsa Cortijo

Member

CHSF - logo

CHSF

Mélanie Jullian

Member

Inserm - Logo

Inserm

Claire Giry

Member

SEM Genopole - Genopole technical platform reception structure

SEM Genopole

Fabrice Taratte

Member

Université Paris-Saclay - Membre de l'AG du GIP Genopole

University Paris-Saclay

Estelle Iacona

Member

Committee For Science, Innovation And Industry (CSII)

The CSII is composed of qualified persons with particular competencies in Genopole’s fields of activity. Its members are approved by the General Meeting. The role of the CSII is to provide the General Meeting with opinions and recommendations on the scientific and industrial orientations of GIP Genopole. A seat on the CSII is accorded intuiti personae and the members act in strict independence of their affiliations.

CSII President

Emmanuelle QUILES
Emmanuelle QUILES, présidente du CSII

Emmanuelle’s current global role at Janssen is to focus on maximizing the value of its pipeline and innovation in 3 therapeutic areas, working closely with R&D. From 2015 to 2021, as Managing Director, she championed the transformation of Janssen France implementing ambitious innovative programs, where she fostered talent development and accelerated employee use of digital solutions for patients’ benefit. She was involved in multiple forums in healthcare innovation where she strongly supported collaborations between private and public healthcare decision makers and supported the innovation ecosystem with a focus on Artificial Intelligence. Before that, she held various positions of increasing responsibility in R&D, commercial and management in linternational pharmaceutical companies and biotech. She is a board member of Business France.

CSII Members

  • Florence Agostino-Etchetto, CEO – Lyonbiopole
  • Emmanuel Barillot, Team Leader – Institut Curie
  • Nadine Bongaerts-Duportet, Administrative Board Member – Hello Tomorrow
  • Fayza Daboussi, Director of Life Sciences – Toulouse White Biotechnology
  • Olivier Dugas, Deputy Technical Lead, Precision Farming – Limagrain
  • Marco Fiorini, General Manager, IA & Cancer Group – PariSanté Campus
  • Philippe Gesnouin, EIT Digital & EIT Health Project Officer – Inrae
  • Xavier Gidrol, Director of the Large Scale Biology laboratory and the Biomics laboratory – CEA
  • David Guerrand, Biotech Business Director – Lallemand
  • Christophe Junot, Research Director – CEA
  • Philippe Lavocat, Chief Executive Officer – GENCI
  • Franck Molina, Director of Public-Private Research Center – SyséDiag (CNRS-Alcediag)
  • Sylvie Ponchaut, Managing Director – BioWin
  • Eric Quemeneur, Executive Vice President and R&D Vice President – Transgene SA
  • Emmanuelle Quilès, Chief Executive Officer – Janssen France
  • Sébastien Ribault, Vice-President – Merck Life Sciences
  • Dominique Stoppa-Lyonnet, Professor of Genetics, Paris-Descartes University, and Head of Genetics – Institut Curie
With the support from
Région île de France